Stephanie Thompson

Cause of Death in Patients with Reduced Kidney Function

Information on common causes of death in people with CKD is limited. We hypothesized that, as eGFR declines, cardiovascular mortality and mortality from infection account for increasing proportions of deaths. We calculated eGFR using the CKD Epidemiology Collaboration equation for residents of Alberta, Canada who died between 2002 and 2009. We used multinomial logistic regression to estimate unadjusted and age- and sex-adjusted differences in the proportions of deaths from each cause according to the severity of CKD. Cause of death was classified as cardiovascular, infection, cancer, other, or not reported using International Classification of Diseases codes. Among 81,064 deaths, the most common cause was cancer (31.9%) followed by cardiovascular disease (30.2%). The most common cause of death for those with eGFR≥60 ml/min per 1.73 m(2) and no proteinuria was cancer (38.1%); the most common cause of death for those with eGFR<60 ml/min per 1.73 m(2) was cardiovascular disease. The unadjusted proportion of patients who died from cardiovascular disease increased as eGFR decreased (20.7%, 36.8%, 41.2%, and 43.7% of patients with eGFR≥60 [with proteinuria], 45-59.9, 30-44.9, and 15-29.9 ml/min per 1.73 m(2), respectively). The proportions of deaths from heart failure and valvular disease specifically increased with declining eGFR along with the proportions of deaths from infectious and other causes, whereas the proportion of deaths from cancer decreased. In conclusion, we found an inverse association between eGFR and specific causes of death, including specific types of cardiovascular disease, infection, and other causes, in this cohort.

Impact of remote location on quality care delivery and relationships to adverse health outcomes in patients with diabetes and chronic kidney disease

BACKGROUND To investigate the relation of residence location, markers of good quality healthcare and adverse clinical outcomes in patients with diabetes and chronic kidney disease (CKD). METHODS We identified 31 337 individuals with diabetes and estimated glomerular filtration rate (eGFR) 15-59 mL/min/1.73 m(2) from a population-based cohort (n= 1 278 375) of adults with serum creatinine measured at least once during 2005 or 2006 in Alberta, Canada. The study population was classified into categories based on travel distance by road from residence location to the closest nephrologist: (0-50, 50.1-100, 100.1-200 and >200 km). RESULTS At follow-up, compared with those living within 50 km, remote dwellers were less likely to visit a nephrologist, less likely to have hemoglobin A1c and urinary albumin measured within 1 year of the index eGFR, and less likely to receive an angiotensin converting enzyme inhibitor, angiotensin receptor blocker or statin (all P < 0.0001). In adjusted models, compared with those with CKD (Stage 3 or 4) living within 50 km, the adjusted likelihood of all-cause hospitalization was [1.4 (95% confidence interval, CI, 1.3-1.6)], [1.3 (95% CI, 1.1-1.6)] and [1.3 (95% CI, 1.2-1.5)]-fold higher for patients living 50.1-100, 100.1-200 and >200 km away from a nephrologist, respectively (P < 0.0001). The hazard ratio of all-cause mortality increased with increasing distance: [1.07 (95% CI, 0.9-1.2)], [1.1 (95% CI, 0.9-1.2)] and [1.2 (95% CI, 1.0-1.4)], respectively (P < 0.0001). CONCLUSIONS Compared with those living closer to a nephrologist, remote dwellers with diabetes and CKD were less likely to receive recommended quality care, and more likely to experience adverse health outcomes.

Higher mortality among remote compared to rural or urban dwelling hemodialysis patients in the United States.

Living far away from specialized care centers is a potential barrier to the delivery of quality health care and has been associated with adverse outcomes. To assess mortality as a function of distance from the closest hemodialysis unit, and as a function of rural rather than urban residence, we analyzed prospectively collected data on 726,347 adults initiating chronic hemodialysis in the United States over a 13-year period. Participants were classified into categories of 0-10 (referent), 11-25, 26-45, 46-100, and remote living over 100 miles from the closest hemodialysis unit. After a median follow-up of 2.7 years (range 0 to 12.7 years), 368,569 patients died. Compared to the referent group, the adjusted hazard ratio of death was 1.01, 0.99, 0.96, and 1.21, respectively. When residence location was classified using rural-urban commuter areas, 16.5, 66.8, and 16.7% of patients lived in urban, micropolitan, and metropolitan areas, respectively. Compared with those living in metropolitan areas, the adjusted hazard ratio of mortality among patients residing in micropolitan and rural communities was 1.02 and 1.01, respectively. Thus, remote but not rural residence was associated with increased mortality among patients initiating chronic hemodialysis treatment in the United States.

Multiple Versus Single and Other Estimates of Baseline Proteinuria Status as Predictors of Adverse Outcomes in the General Population

BACKGROUND The association of proteinuria and adverse clinical outcomes is well established. The optimal method of classifying proteinuria status for study participants in whom it is measured multiple times is unknown, especially when the frequency of measurement varies between participants. STUDY DESIGN Population-based longitudinal study. SETTING & PARTICIPANTS All adults with at least one outpatient serum creatinine measurement in the province of Alberta, Canada. FACTOR Proteinuria (dipstick, albumin-creatinine ratio [ACR]). OUTCOMES All-cause mortality, end-stage renal disease, or doubling of serum creatinine level. MEASURES All outpatient urine dipstick and ACR measurements in the 6-month period before and after the first (index) estimated glomerular filtration rate were used to establish baseline proteinuria. Dipstick measures were analyzed as ceiling (median value up to the next integer), floor (median value down to the next integer), high (single highest dipstick value), low (single lowest dipstick value), and first (first available dipstick value only). Measurements of ACR were evaluated similarly and a median (median of all ACR measurements) value was added. RESULTS Of 920,985 participants, 17% (n = 160,548) had multiple dipstick urinalysis measurements and 22% (n = 22,814) had multiple ACR measurements. With single measurements, absolute rates of mortality and renal outcomes were lower in every proteinuria category compared with multiple measurements. In contrast, the relative increase in rate ratio was greater with increasing proteinuria in patients with single measurements compared with those with multiple measurements. In all classification systems evaluated, more severe proteinuria was associated with significantly higher rates of both outcomes (all P for trend <0.001). LIMITATIONS Lack of a gold standard for choosing between methods. CONCLUSIONS Rates of adverse outcomes related to multiple baseline proteinuria/albuminuria measurements were similar, independent of the measure of baseline proteinuria that was used to combine results. In contrast, discarding follow-up measurements and relying on only the first measurement led to lower estimates of absolute and relative risk for each proteinuria category.

A successful term pregnancy using in-center intensive quotidian hemodialysis.

A 30‐year‐old woman with stage V chronic kidney disease presented at 7 weeks gestation. She had no uremic symptoms; however, blood urea nitrogen (BUN) was 33.6 mg/dL. Because of the well‐established negative relationship between BUN and fetal outcomes, dialysis was initiated with a nocturnal home hemodialysis (NHD)‐like prescription performed in‐center for logistical reasons. She received 36 hours per week of dialysis. Following the initiation of renal replacement therapy, the predialysis BUN was within the normal physiologic range. The patient had an uncomplicated pregnancy with delivery of a healthy 3000 g infant at 39 weeks gestation. This case adds to the growing literature that supports more intensive dialysis in the pregnant women than was previously recommended. This dose of dialysis should be offered to women in an in‐center setting if nocturnal home hemodialysis is not available or feasible.

Quality-of-care indicators among remote-dwelling hemodialysis patients: a cohort study.

BACKGROUND We hypothesized that the higher mortality for hemodialysis patients who live farther from the closest attending nephrologist compared with patients living closer might be due to lower quality of care. STUDY DESIGN Population-based longitudinal study. SETTING & PARTICIPANTS All adult maintenance hemodialysis patients with measurements of quality-of-care indicators initiating hemodialysis therapy between January 2001 and June 2010 in Northern Alberta, Canada. PREDICTORS Hemodialysis patients were classified into categories based on the distance by road from their residence to the closest nephrologist: ≤50 (referent), 50.1-150, 150.1-300, and >300 km. OUTCOMES Quality-of-care indicators were based on published guidelines. MEASUREMENTS Quality-of-care indicators at 90 days following initiation of hemodialysis therapy and, in a secondary analysis, at 1 year. RESULTS Measurements were available for 1,784 patients. At baseline, the proportions of patients residing in each category were 69% for ≤50 km to closest nephrologist; 17%, 50.1-150 km; 7%, 150.1-300 km; and 7%, >300 km. Those who lived farther away from the closest nephrologist were less likely to have seen a nephrologist 90 days prior to the initiation of hemodialysis therapy (P for trend = 0.008) and were less likely to receive Kt/V of 1.2 (adjusted OR, 0.50; 95% CI, 0.30-0.84; P for trend = 0.01). Remote location also was associated with suboptimal levels of phosphate control (P for trend = 0.005). There were no differences in the prevalence of arteriovenous fistulas or grafts or hemoglobin levels across distance categories. LIMITATIONS Registry data with limited data for non-guideline-based quality indicators. CONCLUSIONS Although several quality-of-care indicators were less common in remote-dwelling hemodialysis patients, these differences do not appear sufficient to explain the previously noted disparities in clinical outcomes by residence location.

Dialysis Patients and Critical Illness

Dialysis patients account for 1%-9% of all intensive care unit (ICU) admissions. As a result of the increasing prevalence of patients treated with long-term dialysis and the changing demographics of this population, the number of dialysis patients requiring hospitalization and ICU support is expected to increase. Critically ill dialysis patients have more comorbid conditions and higher severity of illness than the general population, resulting in higher ICU and in-hospital mortality rates, but lower than for critically ill patients with acute kidney injury, suggesting that illness severity may contribute more to adverse outcomes than dialysis status. This review focuses on the epidemiology, prognosis, and short- and long-term outcomes of long-term dialysis patients admitted to the ICU, with data suggesting that dialysis patients have reasonable outcomes after ICU admission compared with the general population. It is important to recognize that illness severity and comorbid conditions rather than dialysis status account for much of the observed differences in short-term mortality rates. There are limited data to guide decision making regarding which dialysis patients may benefit from ICU admission, with common prognostic scoring systems routinely overestimating mortality in dialysis patients.

Relocation of remote-dwellers living with hemodialysis: a time trade-off survey

BACKGROUND There has been little research exploring the experience of dialysis therapy for people living in remote communities. Remote residence location has previously been associated with excess mortality in hemodialysis (HD) patients, suggesting that relocation to a referral center might improve outcomes. It is unknown whether patients view this approach as acceptable. METHODS We studied 121 remote-dwelling chronic HD patients using the time trade-off method applied to hypothetical scenarios. RESULTS Participants indicated that they would trade a median of 6 years of life in their current location (including current social supports) (95% CI 2.25-7) for 10 years of life in a referral center without any of their existing social supports (meaning they would be willing to forgo 4 years of life to remain in their current residence location). When current social supports were assumed to continue in both locations, people were only willing to forego a median of 2 years of life (95% CI 1-4) to remain in their current location. Older participants were much less willing to accept relocation than younger participants; the median time trade-off associated with relocation and without social supports was 2 years for participants aged <50 years, 3 years for those aged 50-69.9 years and 9 years for those aged ≥70 years. CONCLUSIONS Hemodialysis patients currently living remotely were willing to forgo much of their remaining life expectancy rather than relocate-especially among older participants. These findings suggest that decisions about relocation should be accompanied by discussion of anticipated changes in quality of life and life expectancy.

Clinical decision support to improve blood pressure control in hemodialysis patients: a nonrandomized controlled trial.

BACKGROUND Computer-based clinical decision support aims to improve the quality of patient care. The utility of decision support for improving blood pressure control in hemodialysis patients is unknown. METHODS This was a nonrandomized controlled trial of adult patients receiving chronic in-center hemodialysis during the period of April 1, 2005, to September 30, 2006, in 1 of the 2 major university-based renal programs in Alberta, Canada. Physicians in the intervention center were provided with twice-monthly audits and printed management suggestions based on guideline-recommended blood pressure targets. The same data were available to physicians in the control group but without audit and feedback decision support. RESULTS Eight hundred and thirty hemodialysis patients were receiving dialysis treatment at the time the study was initiated. Preintervention and postintervention blood pressure data were available for 361 patients. The primary outcome, the proportion of postdialysis systolic blood pressures at target over 12 months, did not differ between the intervention and the control programs (unadjusted odds ratio 0.59; 95% confidence interval [95% CI], 0.34-1.02, p = 0.06; adjusted odds ratio 0.62; 95% CI, 0.35-1.11, p = 0.11). There was no significant difference between the intervention and control groups in other measures of blood pressure such as the mean change in postdialysis systolic blood pressures (unadjusted mean difference 4 mm Hg, 95% CI, -1 to 9, p = 0.36; adjusted mean difference 2 mm Hg, 95% CI, -1 to 5, p = 0.19). CONCLUSIONS In this population of chronic hemodialysis patients, a computer-based clinical decision support system was not associated with improved blood pressure control.

Renal replacement therapy in the end-stage renal disease patient with critical illness.

Dialysis patients account for 1–9% of all intensive care unit (ICU) admissions. As a result of the increasing prevalence of patients with end-stage renal disease (ESRD) and the changing demographics of this population, the number of dialysis patients requiring hospitalization and ICU support is expected to increase. Critically ill ESRD patients have more comorbidity and higher severity of illness than the general population resulting in higher ICU and in-hospital mortality rates. ESRD patients have been excluded from trials evaluating renal replacement therapy in the ICU, therefore little information is available about the optimal management of renal replacement therapy for dialysis patients in this setting. This review focuses on the epidemiology of chronic dialysis patients admitted to the ICU and discusses an approach to providing renal replacement therapy for critically ill patients with ESRD.